Edwin D. Miska, Director of Equities at First Investors Corporation, says Nu Skin Enterprises, Inc. (NUS) was once of his top performers last year. He touts the company’s success with innovative health products and believes it will be a great growth story.
“They have a line of vitamins and supplements, and they’ve also been getting involved in the beauty and anti-aging area. So they’ve been benefiting from a ‘vanity doesn’t go out of style’ theme via a direct selling model, and Nu Skin has tapped into that quite well,” Miska said.
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Despite a hiccup in China which resulted in Nu Skin’s stock price dropping significantly, Miska still sees strong growth potential for the company.
“They may have grown too quickly, and the Chinese regulators investigated the company,” Miska said. “The regulators asked for improved training and assurances that the sales people are communicating their message within the guidelines that the Chinese government has outlined.”
“We still feel that Nu Skin has a tremendous growth story, and they have a new weight-management product, which they will be rolling out globally, and so we feel that they should be able to put up very good solid growth,” Miska added.
Nu Skin Enterprises (NUS) Stock Rose Fourfold in 2013
January 23, 2014
Sabra Health Care REIT CEO Rick Matros Details the Sabra Health Care REIT Success Story
August 17, 2018
Vet Care: An Attractive Refuge From Health Care
June 14, 2010
Novo Nordisk A/S (ADR) (NVO) Plays to Underlying Health Care Trends as the World Leader in Diabetic Care
October 01, 2013
Acme United Corporation’s (ACU) Record Earnings and Sales Driven by Innovative Products and Acquisitions
June 12, 2013
